Terms: = Colorectal cancer AND GPC3, OCI-5, 2719, ENSG00000147257, SGBS, SGB, DGSX, SDYS, P51654, AC002420_1, SGBS1 AND Diagnosis
11 results:
1. A machine learning tool for identifying non-metastatic colorectal cancer in primary care.
Nemlander E; Ewing M; Abedi E; Hasselström J; Sjövall A; Carlsson AC; Rosenblad A
Eur J Cancer; 2023 Mar; 182():100-106. PubMed ID: 36758474
[TBL] [Abstract] [Full Text] [Related]
2. Impact of a colorectal cancer screening program implantation on delays and prognosis of non-screening detected colorectal cancer.
Cubiella J; Lorenzo M; Baiocchi F; Tejido C; Conde A; Sande-Meijide M; Castro M
World J Gastroenterol; 2021 Oct; 27(39):6689-6700. PubMed ID: 34754161
[TBL] [Abstract] [Full Text] [Related]
3. Cronkhite-Canada syndrome associated with colon cancer metastatic to liver: A case report.
Wang J; Zhao L; Ma N; Che J; Li H; Cao B
Medicine (Baltimore); 2017 Sep; 96(38):e7466. PubMed ID: 28930817
[TBL] [Abstract] [Full Text] [Related]
4. Development of a Time-Resolved Fluorescence Immunoassay for the diagnosis of Hepatocellular Carcinoma Based on the Detection of Glypican-3.
Chen JJ; Xie CM; Wang CR; Wan Y; Dong ZN; Li M; Xu WW
J Fluoresc; 2017 Jul; 27(4):1479-1485. PubMed ID: 28429175
[TBL] [Abstract] [Full Text] [Related]
5. Glypican-3 is useful but not superior to Hep Par 1 in differentiating hepatocellular carcinoma from other liver tumours.
Pour AM; Masir N; Rose IM
Malays J Pathol; 2016 Dec; 38(3):229-233. PubMed ID: 28028292
[TBL] [Abstract] [Full Text] [Related]
6. Immunohistochemical Study of Glypican-3 and HepPar-1 in Differentiating Hepatocellular Carcinoma from Metastatic Carcinomas in FNA of the Liver.
Ibrahim TR; Abdel-Raouf SM
Pathol Oncol Res; 2015 Apr; 21(2):379-87. PubMed ID: 25108409
[TBL] [Abstract] [Full Text] [Related]
7. [Significance of arginase-1, glypican-3, hepatocyte paraffin antigen 1 and alpha-fetoprotein in diagnosis and differential diagnosis of liver tumors].
Li J; Wei L
Zhonghua Bing Li Xue Za Zhi; 2014 Apr; 43(4):246-50. PubMed ID: 24915815
[TBL] [Abstract] [Full Text] [Related]
8. [Significance of glypican-3 immunohistochemistry in diagnosis of hepatocellular carcinoma].
Yip YC; Wang FH; Vong HT; Zhang M; Wen JM
Zhonghua Bing Li Xue Za Zhi; 2011 Sep; 40(9):626-9. PubMed ID: 22177248
[TBL] [Abstract] [Full Text] [Related]
9. Glypican-3 as a potential differential diagnosis marker for hepatocellular carcinoma: a tissue microarray-based study.
Zhang L; Liu H; Sun L; Li N; Ding H; Zheng J
Acta Histochem; 2012 Oct; 114(6):547-52. PubMed ID: 22119409
[TBL] [Abstract] [Full Text] [Related]
10. The glypican 3 oncofetal protein is a promising diagnostic marker for hepatocellular carcinoma.
Yamauchi N; Watanabe A; Hishinuma M; Ohashi K; Midorikawa Y; Morishita Y; Niki T; Shibahara J; Mori M; Makuuchi M; Hippo Y; Kodama T; Iwanari H; Aburatani H; Fukayama M
Mod Pathol; 2005 Dec; 18(12):1591-8. PubMed ID: 15920546
[TBL] [Abstract] [Full Text] [Related]
11. Mouse homologue of a novel human oncofetal antigen, glypican-3, evokes T-cell-mediated tumor rejection without autoimmune reactions in mice.
Nakatsura T; Komori H; Kubo T; Yoshitake Y; Senju S; Katagiri T; Furukawa Y; Ogawa M; Nakamura Y; Nishimura Y
Clin Cancer Res; 2004 Dec; 10(24):8630-40. PubMed ID: 15623647
[TBL] [Abstract] [Full Text] [Related]
